Sol-Gel Technologies

Sol-Gel Technologies is a clinical-stage dermatology company focused on identifying, developing, and commercializing generic drugs for the treatment of skin diseases. Its current portfolio of product candidates includes late-stage branded product candidates that leverage the company’s proprietary silica microencapsulation technology platform, as well as generic product candidates for multiple indications. The company's lead candidate, TWIN, is a novel, once-daily, non-antibiotic topical cream being developed for the treatment of acne vulgaris, or acne.